Format

Send to

Choose Destination
Retrovirology. 2012 Dec 19;9:110. doi: 10.1186/1742-4690-9-110.

Multiple choices for HIV therapy with integrase strand transfer inhibitors.

Author information

1
University Hospital of Nantes, France.

Abstract

Two integrases inhibitors, raltegravir and elvitegravir, have now been approved by regulatory agencies for use in the treatment of HIV-infected patients; and the approval of a third such drug, dolutegravir, is expected during 2013 on the basis of several phase 3 clinical trials. The advent of this new class of antiretroviral (ARV) medications represents a major advance in the management of HIV infection, and each of these three drugs can be expected to continue to be an important component of ARV combination regimens.

PMID:
23253887
PMCID:
PMC3549750
DOI:
10.1186/1742-4690-9-110
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center